| A | Adenine |
| AKT1 | AKT serine/threonine kinase 1 |
| ALS | Acid-labile subunit |
| APC | Adenomatous polyposis coli |
| AS | Antisense |
| BRAF | Proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B |
| BRCA2 | Breast cancer 2 gene |
| C | Cytosine |
| CACNA1G | Calcium channel, voltage-dependent, T type alpha-1G subunit |
| CAFs | Cancer-associated fibroblasts |
| CA19-9 | Carbohydrate antigen 19-9 (cancer antigen 19-9) |
| CEA | Carcinoembryonic antigen |
| CDK1 | Cyclin-dependent kinase 1 |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CEACAM6 | CEA related cell adhesion molecule 6 gene/protein |
| ceRNA | Competing endogenous RNA |
| CI | Confidence interval |
| CIMP | CpG island methylator phenotype |
| CIN | Chromosomal instability |
| CMS | Consensum molecular subtype |
| CRABP1 | Cellular retinoic acid-binding protein 1 |
| CRC | Colorectal cancer |
| CRIS | CRC intrinsic subtype |
| CRND | Colorectal neoplasia differentially expressed |
| CSCs | Cancer stem cells |
| CTCF | CCCTC-Binding Factor (Zinc Finger Protein) |
| DEGs | Differentially expressed genes |
| DMR | Differentially methylated region |
| ECM | Extracellular matrix |
| EGFR | Epidermal Growth Factor Receptor; HER1 in humans |
| eIF4A3 | Eukaryotic initiation factor 4A-III |
| ERBB2 | Erb-B2 Receptor Tyrosine Kinase |
| FSCN1 | Fascin Actin-Bundling Protein 1 |
| G | Guanine |
| GF | Growth factor |
| GH | Growth hormone |
| HMGA1 | High Mobility Group Protein A1 |
| hMLH1 | Human mutL homolog 1 |
| hsa-mir-483 | Stem-loop sequence-micro-RNA-483 |
| HyMiD | Hypermethylation of multiple iDMRs |
| iDMR | Imprinting-associated differentially methylated region |
| IGF1, -2 | Insulin growth factor 1, -2 |
| IGF1R, 2R | IGF Receptor type I, type II |
| IGF2-AS | IGF2 antisense |
| IGF2R/CI-M6PR | IGF2R/Cation-Independent Mannose-6-phosphate Receptor |
| IGFBPs | IGF binding proteins |
| IMPs | IGF2 mRNA-binding Proteins |
| INPP4B | Inositol polyphosphate-4-phosphatase, type II |
| INSR/InsR-A | Insulin receptor/IR isoform-A |
| IR | Insulin Receptor |
| IRS2 | Insulin receptor substrate 2 |
| KRAS | Proto-oncogene K-ras or Ki-ras; from Kirsten Rat Sarcoma Virus |
| lncRNAs | Long non-coding RNAs |
| LOH | Loss of heterozygosity |
| LOI | Loss of imprinting |
| MAPK | A mitogen-activated protein kinase |
| MEK1/2i | Mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor |
| MLH1 | MutL homolog 1 |
| MMR | (DNA) mismatch repair |
| mRNA | Messenger RNA |
| miRNA | MicroRNA |
| MMP2 | Matrix Metallopeptidase 2, matrix metalloproteinase (MMP) gene family |
| MSI | Microsatellite instability |
| MSS | Microsatellite stable |
| mTORC1/2i | Mammalian Target of Rapamycin Complex 1/2 inhibitor |
| NEUROG1 | Neurogenin 1 |
| NICTH | Non-islet cell tumor hypoglycaemia |
| PCNA | Proliferating cell nuclear antigen |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PLAGL2 | Pleomorphic adenoma gene-like 2 |
| PRC2 | Polycomb repressive complex 2 |
| PTEN | Phosphatase and tensin homolog deleted on chromosome ten |
| RB | Retinoblastoma |
| RUNX3 | Runt-related transcription factor 3 |
| SCNA | (DNA) Somatic copy number alteration |
| shRNA | Short hairpin RNA |
| sIGF2R | Soluble IGF Receptor type II |
| SOCS1 | Suppressor of cytokine signaling 1 |
| SSM | Stem/serrated/mesenchymal |
| TCGA | The Cancer Genome Atlas |
| TGF-α, β | Tumor Growth Factor α, β |
| T2DM | Type II Diabetes Mellitus |
| TNM | Tumor-Node-Metastasis |
| TP53 | Tumor gene/protein 53 |
| UTR | Untranslated region |
| VEGF-A | Vascular endothelial growth factor A |
| WNT1 | Wnt (gene wingless + integrated or int-1) Family Member 1 |